Overall, the data in Figure 5 support the model whereby the ERK1/2 pathway is primarily EGFR-driven in vivo and important for EGFR-dependent tumorigenesis, whereas multiple other signaling pathways are largely involved in EGFR-independent tumor growth. Here, MAPK3 is linked to neoplasm.